Takeshi Terazawa

Dr. Takeshi Terazawa


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2021 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
Yasuhide NakayamaYasuhide Nakayama
Yasuhide Nakayama
RHRyuji Higashita
Ryuji Higashita
YSYasuyuki Shiraishi
Yasuyuki Shiraishi
TUTadahi Umeno
Tadahi Umeno
TTTsutomu Tajikawa
Tsutomu Tajikawa
SMSHINJI MIYAMOTO
SHINJI MIYAMOTO
Blood access is a lifeline for dialysis patients. However, serious problems such as stenosis or obstruction of access blood vessels, which are life-threatening conditions in daily clinical practice, still remain. One of the most promising candidates for solving these problems may be Biotube blood vessels. More than 20 years have passed since the development of in-body tissue architecture (iBTA), a technology for preparing tissues for autologous implantation in patients. The tissues obtained by iBTA do not elicit immunological rejection, which is one of the ultimate goals of regenerative medical engineering; however, their practical applications were quite challenging. The seemingly unorthodox iBTA concepts that do not follow the current pre-established medical system may not be readily accepted in general medicine. In contrast, there are many diseases that cannot be adequately addressed even with the latest and most advanced medical technology. However, iBTA may be able to save patients with serious diseases. It is natural that the development of high-risk medical devices that do not fit the corporate logic would be avoided. In order to actively treat such largely unattached diseases, we started Biotube Co., Ltd. with an aim to contribute to society. Biotubes induced by iBTA are collagenous tubular tissues prepared in the patient’s body for autologous implantation. The application of Biotubes as tissues for vascular implantation has been studied for many years. Biotubes may have excellent potential as small-diameter artificial blood vessels, one of the most difficult to clinically achieve. Their possibility is currently being confirmed in preclinical tests. Biotubes may save hundreds of thousands of patients worldwide annually from amputation. In addition, we aim to eliminate the recuring access vascular problems in millions of dialysis patients. This study provides an update on the current development status and future possibilities of Biotubes and their preparation molds, Biotube Makers.

11 January 2022 in EJVES Vascular Forum
Verified
Journal Article
Open access
RHRyuji Higashita
Ryuji Higashita
YNYasuhide Nakayama
Yasuhide Nakayama
YSYasuyuki Shiraishi
Yasuyuki Shiraishi
RIRyosuke Iwai
Ryosuke Iwai
YIYusuke Inoue
Yusuke Inoue
SMSHINJI MIYAMOTO
SHINJI MIYAMOTO
There is a need for small diameter vascular substitutes in the absence of available autologous material. A small diameter, long tissue engineered vascular graft was developed using a completely autologous approach called “in body tissue architecture technology (iBTA)”. The aim of this pilot study was to evaluate “Biotubes”, iBTA induced autologous collagenous tubes, for their potential use as small diameter vascular bypass conduits. Biotubes (internal diameter 4 mm, length 50 cm, wall thickness 0.85 mm) were prepared by subcutaneous embedding of plastic moulds (Biotube Maker) in three goats for approximately two months. Allogenic Biotubes (length 10 cm [n = 2], 15 cm [n = 2], 22 cm [n = 2]) were bypassed to both carotid arteries by end to side anastomosis with their ligation between the anastomoses in another three goats. Residual Biotubes were examined for their mechanical properties. After four weeks, the harvested Biotubes were evaluated histologically. All Biotubes had sufficient pressure resistance, approximately 3000 mmHg. Although wall thickening occurred at two proximal anastomosis sites, all six grafts were patent without luminal thrombus formation, stenosis, or aneurysm deformation throughout the implantation period. Endothelial cells covered both anastomosis sites almost completely, with partial covering in the central portion of the grafts. Furthermore, α smooth muscle actin positive cells infiltrated the middle layer along almost the entire graft length. This preliminary study showed that small diameter, long, tissue engineered Biotubes could function properly as arterial bypass conduits in a large animal for one month without any abnormal change in vascular shape. Thus, small diameter, long Biotubes are potentially viable conduits, which are biocompatible and labour non-intensive, and therefore, suitable for clinical practice. Additionally, Biotubes can start the regeneration process in a short period of time.

1 December 2019 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
YNYasuhide Nakayama
Yasuhide Nakayama
MFMaya Furukoshi
Maya Furukoshi
TTTakeshi Terazawa
Takeshi Terazawa

15 February 2026 in Journal of Japan Society for Fuzzy Theory and Intelligent Informatics
Verified
Journal Article
Open access
PDF file
TTTakeshi Terazawa
Takeshi Terazawa
HSHoshiro Sato
Hoshiro Sato
TAToshiya Arakawa
Toshiya Arakawa
病理画像の組織種セグメンテーションは,高度な専門知識と多大な労力を要する.本研究では,作業者のアノテーション情報を逐次学習し,予測結果を修正することで精度向上を図る対話型セグメンテーションツールを開発した.本ツールはランダムフォレストを用いマッソン・トリクローム染色画像を「細胞核」,「コラーゲン」,「背景」に識別する.ツールの有効性評価のため,専門家よりトレーニングを受けた評価者1名が実験を実施し,IoUとアノテーション操作回数で評価した.その結果,ツールは手作業と同等の精度を維持しつつ作業効率を約1/10に改善した.転移学習による新規画像への適用を試みたところ,明確な効率改善効果は得られなかったが,細胞核認識精度の課題が示唆された.形状特徴量の追加により精度と効率改善が期待される.